Halozyme Therapeutics (NASDAQ:HALO) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $50.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on HALO. TheStreet lowered Halozyme Therapeutics from a b- rating to a c+ rating in a report on Monday, January 22nd. The Goldman Sachs Group lowered their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a neutral rating on the stock in a research note on Thursday, January 18th. StockNews.com raised shares of Halozyme Therapeutics from a hold rating to a buy rating in a research note on Friday, February 23rd. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They issued an outperform rating and a $54.00 price objective for the company. Finally, JMP Securities reissued a market outperform rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $53.29.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $0.09 during trading hours on Tuesday, reaching $39.91. The stock had a trading volume of 902,786 shares, compared to its average volume of 1,209,285. The firm has a market capitalization of $5.07 billion, a PE ratio of 18.91, a price-to-earnings-growth ratio of 0.46 and a beta of 1.26. The firm has a 50-day simple moving average of $39.99 and a 200-day simple moving average of $37.89. Halozyme Therapeutics has a twelve month low of $29.85 and a twelve month high of $45.00. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. As a group, equities analysts forecast that Halozyme Therapeutics will post 3.43 earnings per share for the current year.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares in the company, valued at approximately $6,519,075.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 30,000 shares of company stock worth $1,196,800. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds have recently made changes to their positions in the company. Rise Advisors LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $25,000. Whittier Trust Co. purchased a new position in Halozyme Therapeutics during the first quarter valued at approximately $27,000. Principal Securities Inc. acquired a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $34,000. Fidelis Capital Partners LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $52,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 293 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.